Elite Pharmaceuticals Inc. (OTCMKTS:ELTP – Get Free Report)’s stock price crossed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $0.25 and traded as high as $0.3489. Elite Pharmaceuticals shares last traded at $0.3249, with a volume of 4,629,541 shares trading hands.
Elite Pharmaceuticals Trading Up 32.6%
The company has a debt-to-equity ratio of 0.03, a current ratio of 3.76 and a quick ratio of 2.97. The company has a market cap of $350.07 million, a price-to-earnings ratio of 8.12 and a beta of 0.44. The business’s 50-day simple moving average is $0.25 and its 200-day simple moving average is $0.34.
Elite Pharmaceuticals (OTCMKTS:ELTP – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter. Elite Pharmaceuticals had a net margin of 41.64% and a return on equity of 52.45%.
About Elite Pharmaceuticals
Elite Pharmaceuticals is a specialty pharmaceutical company focused on developing, manufacturing, and marketing generic and branded drug products. Its work includes oral dosage medicines, with an emphasis on controlled-release formulations and products designed to address medication misuse. The company has developed and commercialized prescription products in several therapeutic categories, including treatments for attention-deficit/hyperactivity disorder and pain. Its business also includes advancing additional products through development and regulatory review.
Further Reading
- Five stocks we like better than Elite Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Elite Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elite Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
